BS Brian Skorney Brian Skorney Senior research analyst covering biotechnology at Baird, where he has worked since 2012.

“I love a good short report, because for public dissemination of information, all of the incentives out there are to talk positively. If you have a negative outlook on a company, I do want to hear it. You get a lot more criticism when you're negative on something than when you're positive on something.”

Biotech Hangout · Health & Longevity · November 2026

“I love a good short report, because for public dissemination of information, all of the incentives out there are to talk positively. If you have a negative outlook on a company, I do want to hear it. You get a lot more criticism when you're negative on something than when you're positive on something.” — Brian Skorney, Biotech Hangout

Context

The hosts were discussing a short report that knocked a biotech stock down as much as 20% in a day. Skorney defends short sellers, even though the firm behind the report profits from the drop.

Transcript

Biotech Hangout Around 53:18 into the episode
Tim Opler

…that interesting relative to Abivax and the company, just because it seemed to talk a lot, for example, about preclinical findings for a company that's now reported quite a lot of data. But again, I don't really know. It just didn't seem like that interesting a document to me. I'll say, like,

Matt Gline

…in degree, not a difference in kind relative to like the stuff that happens. And I feel like it's probably the case that there are groups of institutional biotech investors who look down on the short report as a thing while themselves doing fundamentally the same activity in other settings.

Brian Skorney

I will say I love a good short report and I love a good short report because honestly, like for public dissemination of information, all of the incentives out there are to talk positively, right? So, you know, whether, you know, whether I look through Scorpion or another publication's short report and I find them good or bad, you know, different levels of credibility on turning new things or reiterating old things, you know, I appreciate that people will go out there and kind of without the same level of incentives. And there's obviously levels, you know, Scorpion says that they short these stocks and then put these things out. So that, so there is a, you know, a monetary incentive, but it's a hard thing to do. You know, I have sales on stocks. You know, I can be critical of companies, things I'm known for. And it, you know, it kind of hurts to do it. And you get a lot more criticism when you're negative on something than when you're positive on something. So I kind of love the concept of it. I want to, you know, I want to like publicly support the idea of like, if you have a negative…

Tim Opler

Another great conversation.

Matt Gline

Oh, by the way,

Tim Opler

independent of the quality of the short report as like an investing document, as a, if instead it was like an art project designed to troll Twitter, I mean, just like massively successful here,

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout